Clinical update on amisulpride in deficit schizophrenia

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Neuroscience

Background:

• Schizophrenia is a complex mental disorder characterized by positive, negative, and cognitive symptoms.
• Negative symptoms, or deficit symptoms, significantly impair functioning and quality of life in schizophrenia patients.
• Atypical antipsychotics are a class of drugs used to manage schizophrenia, with varying efficacy across symptom domains.

Purpose of the Study:

• To evaluate the efficacy of amisulpride in treating predominantly negative symptoms of schizophrenia.
• To determine the optimal dosage of amisulpride for negative symptom improvement.
• To assess the impact of amisulpride on positive symptoms, depression, and extrapyramidal side effects.

Main Methods:

• Three double-blind studies (two short-term, one medium/long-term) involving 272 schizophrenia patients with predominant negative symptoms.
• Patients were treated with fixed daily doses of amisulpride (50-300 mg) or placebo.
• Symptom severity was assessed using the Scale for the Assessment of Negative Symptoms (SANS) and Scale for the Assessment of Positive Symptoms (SAPS).

Main Results:

• Amisulpride treatment resulted in significant improvement in negative symptoms (SANS scores) compared to placebo.
• Improvements in negative symptoms were not associated with changes in positive symptoms (SAPS scores) or depressive symptoms.
• Extrapyramidal side effects, including parkinsonism, were of low severity and not different from placebo.

Conclusions:

• Amisulpride, particularly at a dose of 100 mg/day, is effective in treating primary negative symptoms of schizophrenia.
• The drug's efficacy appears specific to negative symptoms, without exacerbating other symptom domains.
• These findings support the use of amisulpride for schizophrenia patients experiencing significant deficit symptoms.